🇪🇺 NVP in European Union

EMA authorised NVP on 30 November 2009

Marketing authorisation

EMA — authorised 30 November 2009

  • Application: EMEA/H/C/001119
  • Marketing authorisation holder: Teva B.V.
  • Local brand name: Nevirapine Teva
  • Indication: Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV 1 infected adults, adolescents, and children of any age. Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.
  • Status: withdrawn

Read official source →

Other Infectious Disease / Virology approved in European Union

Frequently asked questions

Is NVP approved in European Union?

Yes. EMA authorised it on 30 November 2009.

Who is the marketing authorisation holder for NVP in European Union?

Teva B.V. holds the EU marketing authorisation.